The Claim

In very high-risk cardiovascular patients, combination therapy with statins and ezetimibe is associated with a statistically significant reduction in all-cause mortality compared to statin monotherapy, with an odds ratio of 0.81 (95% confidence interval: 0.67–0.97).

Source: Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
39score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

For people at very high risk of heart problems, taking both a statin and ezetimibe might help them live longer than taking just a statin alone.

See the scientific wording

In very high-risk cardiovascular patients, combination therapy with statins and ezetimibe is associated with lower all-cause mortality compared to statin monotherapy, with an odds ratio of 0.81 (95% CI: 0.67–0.97), suggesting a statistically significant association with improved survival.

What the research says

1 study

  1. Study: Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis.

    The study looked at whether adding ezetimibe to statins helps high-risk heart patients live longer, and it found that this combo really does lower the chance of dying from any cause.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.